RemeGen Co. Ltd. Class A
688331
Classifica tra le azioni
#2419
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces,... RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of gastric cancer, urothelial carcinoma, breast cancer, and other tumors. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF); RC88, an antibody-drug conjugate (ADC) that targets mesothelin; and RC148, a bispecific antibody ADC drug that in Phase1/2 clinical studies targeting program cell death protein 1 (PD-1) and VEGF; RC278, an ADC drug for the treatment of multiple solid tumors; and RC288, a dual-antibody ADC drug for the treatment of various tumors. The company was founded in 2008 and is headquartered in Yantai, the People's Republic of China.
Prezzo delle azioni
$14.49
Ultima sincronizzazione: 2026-10-16
Capitalizzazione di mercato
$8.11B
Variazione (1 giorno)
0.76%
Variazione (1 anno)
6.06%
Paese
CN
Scambia RemeGen Co. Ltd. Class A (688331)
Categoria
Healthcare
EPS per RemeGen Co. Ltd. Class A (688331)
EPS al June 2026 TTM: $1.51
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di RemeGen Co. Ltd. Class A, l’EPS attuale della società (TTM) è $1.51. Alla fine del 2023, la società aveva un EPS di $-0.40 un aumento rispetto a rispetto a quello del 2022, che era di $-0.27.
Storico EPS per RemeGen Co. Ltd. Class A da 2018 a 2026
EPS alla fine di ogni anno
| Anno | EPS | Cambia |
|---|---|---|
| 2026 (TTM) | $1.51 | -506.95% |
| 2024 | $-0.37 | -5.46% |
| 2023 | $-0.40 | 45.17% |
| 2022 | $-0.27 | -403.79% |
| 2021 | $0.09 | -134.26% |
| 2020 | $-0.26 | 102.63% |
| 2019 | $-0.13 | 58.72% |
| 2018 | $-0.08 | 0.00% |
EPS per aziende simili o concorrenti
| Azienda | EPS | Differenza di EPS | Il paese |
|---|---|---|---|
| $17.32 | 1,050.30% |
US
|
|
| $-7.98 | -629.99% |
US
|
|
| $-5.29 | -451.33% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | 1,742.33% |
NL
|
